Sonio, a MedTech company specializing in women’s and children’s health, has officially been acquired by Samsung Medison after receiving approval from the French Ministry of the Economy and Finance. This acquisition marks a significant milestone for both companies, as they aim to enhance maternal care and expand their global reach.
Sonio, founded in 2020, has quickly become a key player in the healthcare industry, particularly in the field of obstetrics and gynecology. The company has developed an AI-powered reporting and workflow solution that helps clinicians accurately evaluate and document ultrasound exams. This innovative technology has already gained traction in the United States, with Sonio’s system operating in multiple sites across the country.
The acquisition comes on the heels of Sonio’s second wave of FDA clearance in 2024, solidifying its position as a leader in maternal healthcare technology. With the backing of Samsung Medison, Sonio is poised to make even greater strides in the industry.
“Partnering with Samsung Medison gives us an incredible opportunity to advance our mission of improving maternal care worldwide,” said Cécile Brosset, CEO and Co-founder of Sonio. “We plan to continue developing medical reporting technology and diagnostic software, with a particular focus on underserved areas in healthcare.”
Samsung Medison, a global leader in diagnostic imaging devices, sees this acquisition as a strategic move to enhance its ultrasound technology. “The real-time ultrasound exam guidance and quality assurance developed by Sonio are becoming increasingly vital, especially with the workforce shortages in the global healthcare industry,” said Kyu Tae Yoo, CEO of Samsung Medison. “We’re excited to combine our advanced engineering with Sonio’s expertise to introduce next-generation AI technologies that will improve exam quality, efficiency, and patient care.”
Despite the acquisition, Sonio will maintain its independence in commercial growth and continue developing products compatible with all ultrasound device manufacturers. This commitment ensures that healthcare providers and patients globally will benefit from Sonio’s cutting-edge technology.
“We are dedicated to supporting all healthcare providers and patients as we work towards our goal of providing equal access to high-end technology and quality maternal healthcare worldwide,” Brosset added.
Sonio’s journey from a startup to a significant player in the healthcare industry has been supported by early investors such as Elaia, BpiFrance, OneRagtime, Cross Border Impact Ventures, and the EIC Fund. Their AI-enhanced software, particularly the FDA-cleared Sonio Detect product, has set a new standard in prenatal care by ensuring that every ultrasound examination meets the highest quality standards.
For more information about Sonio and its innovative solutions, visit Sonio’s website. To learn more about Samsung Medison and its mission to improve global healthcare, visit Samsung Medison’s website.
